VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Highlights from the San Antonio Breast Cancer Symposium

By E. Roy Berger, MD, FACP
Published: Friday, Jun 18, 2010
Click here to view as PDF.

Reporting on new research and emerging trends

In this month’s issue of Oncology & Biotech News, our editors focus on the 30th Annual San Antonio Breast Cancer Symposium (SABCS), held in December. More than 8,000 clinicians and other breast cancer specialists from around the world attended this year’s conference. The SABCS remains a unique setting for providing cutting edge data on all aspects of breast cancer and premalignant breast disease. Physicians and researchers, as well as other health care professionals, focused on breast cancer research as well as its management and treatment.

In Oncology & Biotech News, our departments provide various perspectives for the oncology professional. For example, in this month’s Physicians’ Financial News, besides providing news from the biotech and pharmaceutical industry, we also profile Novartis and its robust oncology pipeline. As you can see from the article on page 30, Novartis’ pipeline is significant and points to an interesting direction in cancer care. Moreover, the large number of compounds—from various companies— that target a wide variety of cancer types and are in Phase I and II trials will offer oncology professionals numerous cutting-edge products and therapies.

Our other monthly columns—Global Reports, Clinical Trial Reports, The Academy, and Reimbursement and Managed Care News—which appear in this issue are meant to provide the practicing oncologist with the perspective needed to keep abreast of the industry. As with our meeting highlights and news items, these departments provide reports specifically for the community-based oncologist.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Bridging the Gaps Around Oncology Biosimilars: Assessing the Potential Impact of Emerging Agents to PracticeSep 29, 20181.5
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x